Note: Single-source report; awaiting corroboration.
The Centers for Disease Control and Prevention (CDC) announced that its Traveler-Based Genomic Surveillance (TGS) program has surpassed one million voluntary participants. This milestone strengthens the United States' ability to detect and respond to emerging public health threats at its borders.
TGS anonymously collects nasal samples from arriving international travelers at select U.S. airports. The program aims to provide early insights into emerging pathogens and variants before they spread widely within the United States, focusing on seasonal respiratory viruses and other pathogens of public health concern.
Through public-private partnerships with organizations such as Ginkgo Biosecurity and XWell, and in collaboration with select airports, the CDC generates rapid biosurveillance data even when global testing and sequencing information is limited. For example, the program reported the first two detections of influenza H3N2 subclade K to public databases seven days before other publicly available sequences, showcasing its early surveillance value.
Participation in the program is entirely voluntary and anonymous. In addition to traveler samples, the CDC has analyzed over 2,600 airplane wastewater samples to strengthen biosurveillance efforts. These programs support the United States' commitment to global public health leadership by enhancing domestic capabilities, health innovation, and rapid response to infectious disease threats.